A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

2.7K views

⸱

DOI:

10.3791/65109

⸱

April 28th, 2023

 ,  ,  ,  ,  ,  , 

In This Article

Summary

The present protocol describes how to perform 64Cu PET/CT and PET/MRI imaging in humans to study copper-related disorders, such as Wilson disease, and the treatment effect on copper metabolism.

Abstract

Copper is an essential trace element, functioning in catalysis and signaling in biological systems. Radiolabeled copper has been used for decades in studying basic human and animal copper metabolism and copper-related disorders, such as Wilson disease (WD) and Menke's disease. A recent addition to this toolkit is 64-copper (64Cu) positron emission tomography (PET), combining the accurate anatomical imaging of modern computed tomography (CT) or magnetic resonance imaging (MRI) scanners with the biodistribution of the 64Cu PET tracer signal. This allows the in vivo tracking of copper fluxes and kinetics, thereby directly visualizing human and animal copper organ traffic and metabolism. Consequently, 64Cu PET is well-suited for evaluating clinical and preclinical treatment effects and has already demonstrated the ability to diagnose WD accurately. Furthermore, 64Cu PET/CT studies have proven valuable in other scientific areas like cancer and stroke research. The present article shows how to perform 64Cu PET/CT or PET/MR in humans. Procedures for 64Cu handling, patient preparation, and scanner setup are demonstrated here.

Introduction

Copper is a vital catalytic cofactor that drives multiple important biochemical processes essential for life, and defects in copper homeostasis are directly responsible for human diseases. Mutations in the ATP7A or ATP7B genes, encoding copper-transporting ATPases, cause Menke's and Wilson diseases, respectively. Menke's disease (ATP7A) is a rare lethal disorder of intestinal copper hyperaccumulation with severe copper deficiency in peripheral tissues and deficits in copper-dependent enzymes1. Wilson disease (WD) (ATP7B) is a rare disease characterized by the inability to excrete excess copper to bile....

Access restricted. Please log in or start a trial to view this content.

Protocol

A few clinical trials using this 64Cu PET/CT or PET/MRI protocol have been approved by the Regional Ethics Committee of Region Midt, Denmark [1-10-72-196-16 (EudraCT 2016-001975-59), 1-10-72-41-19 (EudraCT 2019-000905-57), 1-10-72-343-20 (EudraCT 2020-005832-31), 1-10-72-25-21 (EudraCT 2021-000102-25), and 1-10-72-15-22 (EudraCT 2021-005464-21)]. Written informed consent was obtained from the participants at enrollment. The inclusion criteria for all participants were age >18, and for females the use of safe contraception. The exclusion criteria for Wilson disease patients were decompensated cirrhosis, a Model for End-stage Liver Disease (MELD) sco....

Access restricted. Please log in or start a trial to view this content.

Results

Dose calculation
Based on dosimetry calculations, the effective radioactivity dose for IV administration is 62 ± 5 µSv/MBq tracer10. Thus, a 50 MBq dose is recommended depending on the time frame. Up to 75-80 MBq is applicable for longer examinations and provides good-quality images without exceeding an ethically approved dose. The effective dose for oral administration is 113 ± 1 µSv/MBq tracer, due to intestinal accumulation of the tracer. Thus, a lower dose needs to be cons.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The method is like any other PET method, but the long half-life of 12.7 h offers the opportunity to investigate long-term copper fluxes (we have good results from up to 68 h after IV tracer injection). All steps in the protocol must be handled by personnel familiar with PET, although they are no more critical than any other PET examination.

Troubleshooting
Because we often use 64Cu for long-term investigations, the PET signal will be noisier than usual. This i.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest.

Acknowledgements

Supported by a grant from The Memorial Foundation of Manufacturer Vilhelm Pedersen & Wife. The foundation played no role in the planning or any other phase of the study.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
0.22 micrometer sterilizing filterMerck Life Science
Cannula 21 G 50 mmBD Microlance301155
Cannula 25 G 16 mmBD Microlance300600
Dose calibratorCapintec CRC-PC calibrator
PET/CT scannerSiemens: Biograph
PET/MR scannerGE Signa
PMOD version 4.0PMOD Technologies LLC
Saline solution 0.9% NaClFresenius Kabi
Sodium acetate trihydrate BioUltraSigma Aldrich71188
Solid 64CuCl2Danish Technical University Risø
Sterile waterFresenius Kabi
Venflon 22 G 25 mmBD Venflon Pro Safety393280

References

  1. Tümer, Z., Møller, L. B. Menkes disease. European Journal of Human Genetics. 18 (5), 511-518 (2010).
  2. Ala, A., Walker, A. P., Ashkan, K., Dooley, J. S., Schilsky, M. L. Wilson's disease. The Lancet. 369 (9559), 397-408 (2007).
  3. Owen, C. A.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Copper PET Imaging64-Copper TracerWilson DiseaseCopper MetabolismPET CTPET MRStandard Uptake ValueKinetic AnalysisCopper BiodistributionZinc Treatment